Sequoia Financial Advisors LLC Acquires Shares of 4,975 ICU Medical, Inc. (NASDAQ:ICUI)

Sequoia Financial Advisors LLC acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,975 shares of the medical instruments supplier’s stock, valued at approximately $496,000.

Several other institutional investors also recently bought and sold shares of ICUI. Wellington Management Group LLP grew its holdings in ICU Medical by 71.6% in the first quarter. Wellington Management Group LLP now owns 1,516,089 shares of the medical instruments supplier’s stock valued at $337,542,000 after purchasing an additional 632,609 shares during the period. FMR LLC grew its holdings in ICU Medical by 89.9% in the third quarter. FMR LLC now owns 1,124,995 shares of the medical instruments supplier’s stock valued at $133,886,000 after purchasing an additional 532,483 shares during the period. Morgan Stanley grew its holdings in ICU Medical by 233.5% in the fourth quarter. Morgan Stanley now owns 679,912 shares of the medical instruments supplier’s stock valued at $107,073,000 after purchasing an additional 476,012 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in ICU Medical by 59.2% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 1,015,006 shares of the medical instruments supplier’s stock valued at $120,796,000 after purchasing an additional 377,532 shares during the period. Finally, Vanguard Group Inc. grew its holdings in ICU Medical by 8.8% in the first quarter. Vanguard Group Inc. now owns 2,122,104 shares of the medical instruments supplier’s stock valued at $472,466,000 after purchasing an additional 171,851 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Christian B. Voigtlander sold 13,603 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $107.19, for a total value of $1,458,105.57. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, COO Christian B. Voigtlander sold 13,603 shares of ICU Medical stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel Woolson sold 791 shares of ICU Medical stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $98.27, for a total value of $77,731.57. Following the transaction, the vice president now owns 13,980 shares in the company, valued at approximately $1,373,814.60. The disclosure for this sale can be found here. Insiders have sold a total of 24,262 shares of company stock worth $2,545,532 over the last quarter. 6.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, KeyCorp raised their target price on ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $123.00.

ICU Medical Stock Performance

NASDAQ ICUI opened at $96.33 on Wednesday. The company has a market cap of $2.35 billion, a PE ratio of -78.32 and a beta of 0.69. The stock’s 50 day simple moving average is $102.48 and its 200-day simple moving average is $98.81. ICU Medical, Inc. has a 1-year low of $78.28 and a 1-year high of $212.43. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.53 and a quick ratio of 1.06.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.39. The business had revenue of $587.86 million for the quarter, compared to the consensus estimate of $564.77 million. ICU Medical had a positive return on equity of 6.35% and a negative net margin of 1.31%. As a group, equities research analysts anticipate that ICU Medical, Inc. will post 3.52 EPS for the current fiscal year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.